All News

EULAR19.abstract.jpg (keep)

Featured Abstracts from Industry at EULAR 2021

Jack Cush, MD

Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Read Article
gout podagra inflammed

Best Interventions for Gout Flares

Jack Cush, MD

A recent metanalysis assessed the comparative efficacy of current first-line pharmacologic antiinflammatory interventions for gout flares and surmised that canakinumab and intravenous or intramuscular corticosteroids are superior to  nonsteroidal antiinflammatory drugs [NSAIDs].

Read Article
pill,ASA,colchcine,small

COLCORONA: Protective Effect of Colchicine in COVID-19

Jack Cush, MD

Lancet Respiratory Medicine has reported the results of the COLCORONA trial, showing that in patients with PCR-confirmed COVID-19 infection, colchicine led to a significantly lower rate of death or hospital admission from COVID.

Read Article
RheumNow Podcast square

RheumNow Podcast – Myth Busters (5.21.2021)

Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Read Article
RheumNow Podcast square

RheumNow Podcast – BandAids for Rheumatologists (5.14.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.



We love Rheumatology!

Read Article
RNL, over, microphone

RheumNow Live 2021 Now Available for All

Jack Cush, MD

RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).

Read Article
RheumNow Podcast square

RheumNow Podcast – Falling or Falling in Love?

Jack Cush, MD

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

Read Article
640px-Fluorescent_uric_acid.JPG

Uric Acid: A Major Player in the Metabolic Syndrome

Jack Cush, MD

An open source, free read from the European Journal of Internal Medicine discusses how uric acid has evolved from the toxic cause of gout and nephrolithiasis and evolved, by way of science, into a pleiotropic recidivist in the evolution of obesity, diabetes, insulin resistance, renal disease, hypertension, fatty liver, and cardiovascular disease.

Read Article
RheumNow Podcast square

RheumNow Podcast – Uppers and Downers

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
RheumNow Podcast square

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Jack Cush, MD

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article
heart-attack.jpg

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Jack Cush, MD

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.

Read Article
BP

Hypertension Unaffected by Urate Lowering Therapy

Jack Cush, MD

Does uric acid contribute to the risk of hypertension (HTN)?  A recent cohort trial shows that allopurinol in young adults does not sufficiently lower blood pressure (BP).

Read Article
Study of National inpatient sample database (2015 to 2017) showed the frequency of atrial fibrillation in rheumatic disease (RD) pts finding that AF frequency highest in gout followed by vasculitis, and PMR. RD Mortality was 2 fold higher with AF. https://t.co/enno6hrKOI

Links:

Dr. John Cush RheumNow ( View Tweet)

News: Factors Associated with COVID-19 Deaths in Rheumatic Patients https://t.co/FzsINtpZEz https://t.co/QzuLZRKaZy

Links:

Dr. John Cush RheumNow ( View Tweet)
"Arthritis Mutilans" - worse outcome to chronic inflammatory arthritis is due to 5 disorders: 1) RA 2) Psoriatic arthritis 3) Tophaceous gout 4) polyarticular JIA 5) Multicentric reticulohistiocytosis (Ive never seen this!!) https://t.co/XYmBEW1F0R https://t.co/tGWNG9Aklw

Links:

Dr. John Cush RheumNow ( View Tweet)

A retrospective cohort study of 419 gout patients compared low dose 0.6 mg qd (LD) vs regular 0.6 mg bid (RD) colchicine as prophylaxis when starting urate lowering therapy. Rate of gout flares were roughly equal (LD 14.3% vs RD 11.3%) https://t.co/8G6siQlHbI

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Uric Acid: A Major Player in the Metabolic Syndrome Uric acid, and hyperuricemia, has been closely linked with may of the components of the metabolic syndrome, which is largely a consequence of excessive fat storage. https://t.co/ObQ0LURodb https://t.co/HT35ODnFkn

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is Up! – with news of Uppers and Downers. Read about Vaccine success, CKD gout prophylaxis, TOFA in AS & too much IL-17 inhib can be a problem https://t.co/kt63YrQ0Sw Listen iTunes> https://t.co/FHJv01AAbC or Android SoundCloud>>https://t.co/IyYvjkWUc1

Links:

Dr. John Cush RheumNow ( View Tweet)

Gout Prophylaxis in patients with severe CKD? Metanalysis of 33 studies suggests 1) lack of good data guidance; 3) Colchicind is associated w/ toxicity w/ CKD (neuromyopathy, rhabdomyolysis; 3) anakinra - works, expensive, little/no toxicity https://t.co/VhI0wRC0VO

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of 32 studies shows most forms of arthritis assoc w/ incr risk of CVA (ischemic stroke: RR=1.53 or hemorrhagic stroke: RR=1.45), esp for RA (RR=1.38), AS (RR=1.49), PsA (RR=1.33), gout (RR=1.4) --risk higher with age <45 years (RR=1.46) https://t.co/YDiebrqtbi

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×